Home › Myasthenia Gravis › California › Los Angeles
Myasthenia Gravis clinical trials in Los Angeles, CA
4 studies for Myasthenia Gravis are looking for participants at sites in and around Los Angeles (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
RecruitingPhase 3
- Site Number - 1023, Los Angeles
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
RecruitingPhase 2/3
- Ronald Reagan UCLA Medical Center, Los Angeles
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
RecruitingPhase 3
- University of Southern California, Los Angeles
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
RecruitingPhase 1
- UCLA Medical Center, Los Angeles
About Myasthenia Gravis
Myasthenia gravis (MG) is an autoimmune disease that weakens the muscles under your control. Find out about MG causes, symptoms, and treatment.
More about Myasthenia Gravis on MedlinePlus
Myasthenia Gravis trials in other cities
- Tampa, FL12 studies
- Houston, TX11 studies
- Durham, NC10 studies
- Boca Raton, FL10 studies
- Columbus, OH8 studies
- Miami, FL7 studies
- New York City, NY7 studies
- Milwaukee, WI7 studies
- St. Louis, MO7 studies
- Boston, MA6 studies
- Washington, DC6 studies
- San Francisco, CA6 studies
Other studies in Los Angeles
- Non-Small Cell Lung Cancer87 studies
- Cancer (all types)74 studies
- Breast Cancer73 studies
- Prostate Cancer61 studies
- Colorectal Cancer59 studies
- Metastatic Cancer57 studies
- Ovarian Cancer50 studies
- Lung Cancer45 studies
- Head and Neck Squamous Cell Carcinoma42 studies
- Pancreatic Cancer35 studies
- Endometrial Cancer34 studies
- Melanoma34 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.